Handelsbanken Fonder AB Lowers Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Handelsbanken Fonder AB lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 538,524 shares of the medical research company’s stock after selling 96,304 shares during the quarter. Thermo Fisher Scientific makes up 0.8% of Handelsbanken Fonder AB’s investment portfolio, making the stock its 19th largest holding. Handelsbanken Fonder AB owned approximately 0.14% of Thermo Fisher Scientific worth $269,994,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. High Note Wealth LLC grew its holdings in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares in the last quarter. Swiss RE Ltd. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $28,000. Legacy Wealth Managment LLC ID raised its stake in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares in the last quarter. Birchwood Financial Partners Inc. purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at $29,000. Finally, Core Wealth Advisors LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter worth $30,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher received FDA clearance for a multiple myeloma testing platform, strengthening its position in clinical diagnostics and potentially expanding adoption among hospitals, laboratories, and pharmaceutical companies. The development reinforces the company’s broader growth strategy in precision medicine. How Investors Are Reacting To Thermo Fisher Scientific New FDA-Cleared Multiple Myeloma Platform
• Positive Sentiment: Thermo Fisher expects its India customer base to grow 15% to 20% over the next five years as biopharmaceutical research and manufacturing expand in the country. The outlook points to a meaningful long-term international growth opportunity for the company’s instruments, services, and bioproduction businesses. Thermo Fisher Eyes India Customer Growth
• Positive Sentiment: Comparative coverage emphasizes Thermo Fisher’s stronger recent positioning in a potential recovery of pharmaceutical and biotechnology research spending. The company exceeded second-quarter expectations, raised guidance, and reported broad-based demand improvement, factors that can support investor confidence relative to peers such as Danaher. Thermo Fisher vs. Danaher
• Neutral Sentiment: Articles comparing Thermo Fisher with Abbott and Azenta frame the investment decision around diversification, valuation, and exposure to a life-sciences spending recovery. These are investor-perspective pieces rather than new company announcements, so their direct effect on TMO is limited. Abbott vs. Thermo Fisher Thermo Fisher and Azenta Comparison
• Negative Sentiment: CEO Marc Casper and Chief Accounting Officer Joseph Holmes sold shares. Both transactions were disclosed as part of planned trading activity, reducing the likelihood that the sales signal deteriorating business prospects, but insider selling can still create modest short-term sentiment pressure. Thermo Fisher Insider Trading Filing

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $598.68 on Tuesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The company has a market capitalization of $221.36 billion, a price-to-earnings ratio of 32.20, a price-to-earnings-growth ratio of 2.42 and a beta of 0.84. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The firm has a 50-day simple moving average of $519.74 and a 200-day simple moving average of $509.70.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business’s revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is 10.11%.

Wall Street Analyst Weigh In

TMO has been the topic of a number of analyst reports. Evercore set a $570.00 price target on Thermo Fisher Scientific in a research report on Monday, July 6th. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price target for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Finally, Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $619.41.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 4,608 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $586.12, for a total value of $2,700,840.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 26,553 shares of company stock valued at $15,343,589 over the last three months. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.